Morepen Laboratories Ltd. on Thursday, April 24, 2025, announced the launch of four new pharmaceutical products—Ticapen, UdoFix, LycoMore, and Acifix—marking a strategic expansion of its branded formulations business in India. This move follows the March launch of Empamore and reflects the company’s aggressive push toward innovation-driven, specialty-focused therapeutics.
Product details and therapeutic focus
The newly launched drugs span across critical care segments, including cardiology, hepatology, nutrition, and gastroenterology, and have been developed using in-house APIs at Morepen’s USFDA-approved manufacturing facilities.
Ticapen (Ticagrelor 60/90 mg)
A next-gen antiplatelet therapy for ACS, Angina, and MI, offering:
-
Patient-friendly 4×14 pack
-
Day/Night markers for adherence
-
Premium matte foil packaging
-
Competitive pricing
UdoFix (Ursodeoxycholic Acid 150/300 mg)
For liver care and hepatoprotection:
-
98.23% superior dissolution rate
-
Anti-counterfeit packaging
-
₹39.9/tab vs ₹57.1/tab for market leaders
LycoMore Syrup
A science-backed nutraceutical syrup enriched with Lycopene, essential vitamins, and minerals:
-
Pleasant taste, no foul odor
-
Enhanced shelf life with glass packaging
Acifix Raft Suspension
An innovative acid-reflux treatment:
-
Quick-action raft mechanism
-
Unique paan flavor for better compliance
-
Targets GERD and heartburn symptoms effectively
Strategic push in formulations
With a current formulation business size of ₹325 crore, Morepen is targeting ₹1,000 crore in the next five years, backed by a growing field force, expanded product range, and deeper doctor engagement across geographies. Nationwide awareness campaigns, CME programs, and collaborations with healthcare professionals are part of this push.
Global footprint and R&D strength
Morepen remains India’s #1 API exporter for six globally used molecules, including Loratadine, Atorvastatin, and Rosuvastatin, with a presence in 82 countries and a 144 MT annual API capacity. Its integrated supply chain and research capabilities offer a strong edge in both regulated and emerging markets.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or medical advice. Please consult a healthcare professional for medical treatment or investment advisor for financial decisions.
